FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases. The gene discussed is FASLG; the disease is metastatic malignant neoplasm in the lymph nodes.